QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data // New software advances precision medicine by enabling smaller and decentralized labs to adopt NGS testing with efficiency, consistency and confidence // Combination of QCI Secondary Analysis and QCI Interpret provide a secure and compliant environment for trusted and scalable bioinformatics workflows for oncology and inherited disease applications.

QCI二次分析一种直接与QCI-Interpret集成的基于云的软件，可以对临床下一代测序数据进行高通量二次分析//新软件通过使小型和分散的实验室能够高效，一致和自信地采用NGS测试来推进精准医学//QCI二次分析和QCI-Interpret的结合为肿瘤学和遗传疾病应用的可信和可扩展的生物信息学工作流程提供了一个安全且兼容的环境。

Venlo, the Netherlands, and Redwood City, California, May 02, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of QCI Secondary Analysis, a cloud-based software-as-a-services (SaaS) solution enabling high-throughput secondary analysis for use with any clinical next-generation sequencing (NGS) data..

2024年5月2日，荷兰芬洛和加利福尼亚州红木城（环球通讯社）--QIAGEN（纽约证券交易所：QGEN；法兰克福主要标准：QIA）今天宣布推出QCI二次分析，这是一种基于云的软件即服务（SaaS）解决方案，可用于任何临床下一代测序（NGS）数据的高通量二次分析。。

This turnkey service supports all QIAGEN QIAseq panels and seamlessly integrates with QCI Interpret, QIAGEN’s clinical variant interpretation and reporting software, to deliver highly scalable and customizable Sample to Insight workflows for oncology and inherited disease applications.

这项交钥匙服务支持所有QIAGEN QIAseq面板，并与QIAGEN的临床变异解释和报告软件QCI Interpret无缝集成，为肿瘤学和遗传疾病应用提供高度可扩展和可定制的样本到洞察力工作流程。

Typically, sequencing data is processed in three phases: After the signals registered by the NGS device have initially been translated into digital information (primary analysis), the DNA fragments encoded must be merged into a connected sequence and analyzed for variants in relation to a human reference genome (secondary analysis).

通常，测序数据分三个阶段进行处理：在NGS设备注册的信号最初被翻译成数字信息（初步分析）后，编码的DNA片段必须合并成一个连接的序列，并分析与人类参考基因组相关的变异（二次分析）。

In the third and final step (tertiary analysis), the identified variants are interpreted in the context of a specific clinical picture..

在第三步也是最后一步（三级分析）中，将在特定临床情况下解释已识别的变体。。

“Our goal is to empower molecular testing labs, regardless of size, budget, and experience, to leverage the power of comprehensive genomic information to advance precision medicine in every setting,” said Jonathan Sheldon, Senior Vice President of QIAGEN Digital Insights. “Due to NGS adoption barriers, including complexity and cost, a vast majority of small- to mid-size molecular laboratories rely on limited single-gene tests or choose to outsource sample testing for more comprehensive NGS analysis.

QIAGEN Digital Insights高级副总裁乔纳森·谢尔顿（JonathanSheldon）表示：“我们的目标是增强分子检测实验室的能力，无论其规模、预算和经验如何，都能利用全面基因组信息的力量，在各种情况下推进精准医学。”。“由于NGS的采用障碍，包括复杂性和成本，绝大多数中小型分子实验室依赖有限的单基因测试，或者选择将样本测试外包以进行更全面的NGS分析。

However, with the launch of our new NGS secondary analysis software, we are making NGS testing more accessible to decentralized labs.”.

然而，随着我们新的NGS二次分析软件的推出，我们正在使分散实验室更容易进行NGS测试。”。

“QCI Secondary Analysis is particularly valuable for labs looking to start running NGS-based tests because it’s a turnkey solution with easy-to-use features for the everyday lab technician,” said Can Koşukcu, Senior Bioinformatics Application Scientist of DiagnoSeq, an early-access customer of QCI Secondary Analysis.

“QCI二次分析对于希望开始运行基于NGS的测试的实验室特别有价值，因为它是一个交钥匙解决方案，对于日常实验室技术人员来说具有易于使用的功能，”DiagnoSeq的高级生物信息学应用科学家Can Koşukcu说，DiagnoSeq是QCI二次分析的早期访问客户。

“With the availability of this new solution, QIAGEN has simplified the whole bioinformatics pipeline, providing an integrated workflow that minimizes resource investment and maximizes productivity.”.

“有了这个新解决方案，QIAGEN简化了整个生物信息学流程，提供了一个集成的工作流程，可以最大程度地减少资源投资并提高生产力。”。

Expanding on the QIAGEN Clinical Insights (QCI) portfolio, QCI Secondary Analysis is designed to streamline analysis from a range of assay types, enabling labs to process more sequencing data without extensive time and resource investment. The turnkey solution is deployed on the QIAGEN Clinical Cloud, a secure cloud environment ensuring the highest degree of isolation and data protection, including compliance with ISO 27001, General Data Protect Regulation (GDPR), and the Health Insurance Portability and Accountability Act (HIPPA) requirements..

QCI二次分析扩展了QIAGEN Clinical Insights（QCI）组合，旨在简化一系列分析类型的分析，使实验室能够处理更多的测序数据，而无需大量的时间和资源投资。交钥匙解决方案部署在QIAGEN Clinical Cloud上，QIAGEN Clinical Cloud是一个安全的云环境，可确保最高程度的隔离和数据保护，包括符合ISO 27001、通用数据保护法规（GDPR）和健康保险便携性和责任法案（HIPPA）的要求。。

While QCI Secondary Analysis is a plug-in-play solution that can support any panel, NGS instrument or software, the true value of this new offering is how it complements QIAGEN’s Sample to Insight portfolio. QCI Secondary Analysis is validated for use for all QIAseq panels, can be used with LightSpeed Clinical, a new software module within QIAGEN CLC Genomics Workbench Premium that enables ultra-fast NGS analysis, and directly integrates with QCI Interpret, QIAGEN’s variant interpretation and reporting platform that has been trusted to analyze and interpret more than 3.5 million NGS patient test cases worldwide..

虽然QCI二次分析是一种即插即用解决方案，可以支持任何面板、NGS仪器或软件，但这一新产品的真正价值在于它如何补充QIAGEN的Sample to Insight产品组合。QCI二次分析已验证可用于所有QIAseq面板，可与LightSpeed Clinical一起使用，LightSpeed Clinical是QIAGEN CLC Genomics Workbench Premium中的一个新软件模块，可实现超快NGS分析，并直接与QCI Interpret集成，QIAGEN的变体解释和报告平台已被信任可分析和解释全球350多万NGS患者测试案例。。

QIAGEN Digital Insights solutions are used by national precision medicine programs worldwide to process over 850,000 clinical samples per year. They enable researchers and clinicians to access advanced tools for data processing and interpretation, empowering them to make well-informed decisions that lead to improved research results.

QIAGEN Digital Insights解决方案被全球国家精准医学计划使用，每年处理超过850000个临床样本。它们使研究人员和临床医生能够访问先进的数据处理和解释工具，使他们能够做出明智的决策，从而改进研究结果。

QDI offers automated workflows, scalability, and efficient turnaround times, as well as solutions tailored to fit any lab, database, API, service, or workflow application..

QDI提供自动化的工作流程、可扩展性和高效的周转时间，以及针对任何实验室、数据库、API、服务或工作流程应用程序量身定制的解决方案。。

More information on QIAGEN’s Sample to Insight solutions and the new QCI Secondary Analysis service can be found here.

有关QIAGEN的Sample to Insight solutions和新的QCI二次分析服务的更多信息，请参见此处。

About QIAGEN

关于QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials.

QIAGEN N.V.是一家总部位于荷兰的控股公司，是全球领先的样本到见解解决方案提供商，该解决方案使客户能够从包含生命构建模块的样本中获得有价值的分子见解。我们的样品技术从血液、组织和其他材料中分离和处理DNA、RNA和蛋白质。

Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics).

分析技术使这些生物分子可见并准备进行分析。生物信息学软件和知识库解释数据以报告相关的可行见解。自动化解决方案以无缝且经济高效的工作流将这些功能结合在一起。QIAGEN在分子诊断（人类保健）和生命科学（学术界、制药研发和工业应用，主要是法医学）方面为全球50多万客户提供解决方案。

As of March 31, 2024, QIAGEN employed more than 5,900 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com..

截至2024年3月31日，QIAGEN在全球35多个地点雇用了5900多人。有关更多信息，请访问http://www.qiagen.com..

Forward-Looking Statement

前瞻性声明

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks.

本新闻稿中的某些声明可能被视为1933年《美国证券法》第27A节（经修订）和1934年《美国证券交易法》第21E节（经修订）所指的前瞻性声明。如果本文中包含的与QIAGEN产品、发布和开发时间、营销和/或监管批准、财务和运营前景、增长和扩张、合作、市场、战略或运营结果（包括但不限于其预期的调整后净销售额和调整后的稀释收益结果）有关的任何声明都是前瞻性的，则此类声明基于当前的预期和假设，涉及许多不确定性和风险。

Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competito.

此类不确定性和风险包括但不限于与增长管理和国际运营相关的风险（包括货币波动的影响、监管流程和对物流的依赖）、经营成果的可变性和客户类别之间的分配、我们的产品在学术界、制药、应用测试和分子诊断领域的客户市场的商业开发；改变与客户、供应商和战略合作伙伴的关系；竞争；技术的快速或意外变化；QIAGEN产品需求波动（包括一般经济状况、客户资金水平和时间、预算和其他因素引起的波动）；我们获得产品监管批准的能力；成功将QIAGEN的产品应用于集成解决方案并生产此类产品的困难；QIAGEN识别和开发新产品的能力，以及区分和保护我们的产品免受竞争的能力。

Source: QIAGEN N.V.

资料来源：QIAGEN N.V。

Category: Corporate

类别：公司

John Gilardi QIAGEN N.V. +49 2103 29 11711 ir@qiagen.com Domenica Martorana QIAGEN N.V. +49 2103 29 11244 ir@qiagen.com Thomas Theuringer QIAGEN N.V. +49 2103 29 11826 pr@qiagen.com Daniela Berheide QIAGEN N.V. +49 2103 29 11676 pr@qiagen.com

John Gilardi QIAGEN N.V.+49 2103 29 11711ir@qiagen.comDomenica Martorana QIAGEN N.V.+49 2103 29 11244ir@qiagen.comThomas Theuringer QIAGEN N.V.+49 2103 29 11826pr@qiagen.comDaniela Berheide QIAGEN N.V.+49 2103 29 11676pr@qiagen.com